Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24872313 | 1.00 | PTGS1 (0.44) | PTGS1PTGS2ATMLMNAFABP4 | |
| SCHEMBL23482800 | 0.92 | PTGS1 (0.40) | PTGS1PTGS2ATMLMNAFABP4 | |
| SCHEMBL23482804 | 0.88 | PTGS1 (0.50) | PTGS1PTGS2ATMLMNAMAPK1 | |
| SCHEMBL23451319 | 0.88 | PTGS1 (0.50) | PTGS1PTGS2ATMLMNAMAPK1 | |
| SCHEMBL23482534 | 0.87 | PTGS1 (0.52) | PTGS1PTGS2ATMLMNAMAPK1 | |
| SCHEMBL25939244 | 0.87 | PTGS1 (0.52) | PTGS1PTGS2ATMLMNAMAPK1 | |
| SCHEMBL23451312 | 0.87 | PTGS1 (0.52) | PTGS1PTGS2ATMLMNAMAPK1 | |
| SCHEMBL25130218 | 0.87 | PTGS1 (0.52) | PTGS1PTGS2ATMLMNAMAPK1 | |
| SCHEMBL25940535 | 0.86 | PTGS1 (0.41) | PTGS1PTGS2ATMLMNAAKT1 | |
| SCHEMBL30396758 | 0.84 | PTGS1 (0.53) | PTGS1PTGS2ATMLMNAFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | PTGS1 3834/4885PTGS2 2819/4885ATM 3786/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | PTGS1 3350/4885PTGS2 4141/4885ATM 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.